Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Merit Medical Systems (MMSI)

Merit Medical names Martha Aronson CEO; preliminary Q2 revenue up 12% to 14%

Positive Impact 4 of 5 leadership Written later

Merit Medical said on July 7, 2025 that Martha Aronson will become President and CEO effective October 3, 2025, succeeding Fred Lampropoulos, who will remain Chairman. The company also reported preliminary, unaudited second-quarter revenue of approximately $380 million to $384 million, up about 12% to 14% from the prior-year quarter, with constant currency growth of about 11% to 13%. The revenue figures are not audited and may change when full results are released on July 30, 2025.

Key points

  • Martha Aronson to succeed Fred Lampropoulos as CEO effective October 3, 2025; Lampropoulos remains Chairman
  • Aronson offer includes a $1,000,000 base salary, a $250,000 signing bonus and a target annual bonus of 100% of salary
  • Initial equity award with a target grant-date fair value of $5,500,000, plus a $4,125,000 award on commencement of employment
  • Preliminary Q2 revenue of approximately $380 million to $384 million versus $338.0 million a year earlier; full results due after market close July 30, 2025

The filing

CompanyMerit Medical Systems (MMSI)
Form8-K, current report
Filed with the SECJul 11, 2025, 4:07 PM ET
Accession number0000856982-25-000041

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.